Scientific
publications

Selected Publications

• Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)
  Kristina Drott, Hagberg, H., Papworth, K., Relander, T. & Mats Jerkeman, 2018 jun 26, I : Blood Advances. 2, 12, s. 1386-1392 7 s.

• The HDAC inhibitor valproate induces a bivalent status of the CD20 promoter in CLL patients suggesting distinct epigenetic regulation of CD20 expression in CLL in vivo.
  Scialdone, A., Hasni, M. S., Damm, J. K., Lennartsson, A., Urban Gullberg & Kristina Drott, 2017, I : Oncotarget.8, 23, s. 37409-37422 14 s.

• Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo.
  Kofoed Damm, J., Gordon, S., Mats Ehinger, Mats Jerkeman, Urban Gullberg, Anne Hultquist & Kristina Drott, 2015, I : Experimental hematology & oncology. 4, 4

• The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
  Malin Ageberg, Karin Rydström, Thomas Relander and Kristina Drott
  Am J Transl Res 5(2):170-83 (2013) PMID 23573362